<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04905979</url>
  </required_header>
  <id_info>
    <org_study_id>APX-002</org_study_id>
    <nct_id>NCT04905979</nct_id>
  </id_info>
  <brief_title>Trial of AD113 and Atomoxetine in OSA Patients With Hypertension</brief_title>
  <official_title>Randomized Double-Blind 2-Period Multiple Dose Crossover Study to Evaluate the Efficacy and Safety of AD113 vs Atomoxetine in OSA Patients With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apnimed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apnimed</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blind, 2-period, non placebo-controlled crossover study in&#xD;
      patients with moderate to severe OSA and controlled hypertension, comparing atomoxetine with&#xD;
      AD113&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to examine the efficacy and safety of AD113 to treat obstructive sleep&#xD;
      apnea with hypertension. The study is a two-period multi-dose randomized crossover design in&#xD;
      which patients will undergo overnight polysomnographic (PSG) testing with dosing of one of&#xD;
      the following 2 treatments: AD113 for 10 days or Atomoxetine for 10 days. Participants will&#xD;
      return 1 week after their final crossover PSG for an end of study (EOS) Visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hypoxic burden (HB, total area under the respiratory event-related desaturation curve)</measure>
    <time_frame>10 days of treatment per crossover arm</time_frame>
    <description>Change in HB for AD113 vs. atomoxetine measured by polysomnography atomoxetine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Apnea-Hypopnea Index (AHI, average number of events for every hour of sleep)</measure>
    <time_frame>10 days of treatment per crossover arm</time_frame>
    <description>Change in AHI for AD113 vs. atomoxetine measured by polysomnography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>AD113</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two oral capsules administered before bed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atomoxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two oral capsules administered before bed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AD113</intervention_name>
    <description>Two oral capsules administered before bed</description>
    <arm_group_label>AD113</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine</intervention_name>
    <description>Two oral capsules administered before bed</description>
    <arm_group_label>Atomoxetine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between 25 to 65 years of age, inclusive, at the Screening Visit.&#xD;
&#xD;
          -  AHI 10 to 50 (hypopneas defined by 4% oxygen desaturation)&#xD;
&#xD;
          -  History of hypertension controlled with 1 - 2 medications,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of narcolepsy.&#xD;
&#xD;
          -  Clinically significant craniofacial malformation.&#xD;
&#xD;
          -  Clinically significant cardiac disease (e.g., rhythm disturbances, coronary artery&#xD;
             disease or cardiac failure) or hypertension requiring more than 2 medications for&#xD;
             control. A medication for these purposes is defined by dosage form, such that a&#xD;
             combination antihypertensive medication is considered 1 medication&#xD;
&#xD;
          -  CPAP should not be used for at least 2 weeks prior to first study PSG&#xD;
&#xD;
          -  History of using oral or nasal devices for the treatment of OSA may enroll as long as&#xD;
             the devices are not used during participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PCCAB</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21286</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart King</last_name>
      <phone>410-494-1662</phone>
      <email>sking@pccabpa.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

